Analysts expect that Strongbridge Biopharma (NASDAQ:SBBP) will report earnings of ($0.41) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Strongbridge Biopharma’s earnings, with the highest EPS estimate coming in at ($0.40) and the lowest estimate coming in at ($0.42). Strongbridge Biopharma posted earnings of ($0.33) per share in the same quarter last year, which indicates a negative year over year growth rate of 24.2%. The firm is expected to announce its next earnings report before the market opens on Thursday, May 10th.
On average, analysts expect that Strongbridge Biopharma will report full year earnings of ($1.96) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.73). For the next year, analysts expect that the company will post earnings of ($1.74) per share, with EPS estimates ranging from ($1.82) to ($1.65). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Strongbridge Biopharma.
Get Strongbridge Biopharma alerts:
Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25).
SBBP has been the subject of a number of research reports. BidaskClub raised shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Zacks Investment Research raised shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, April 6th. ValuEngine raised shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price target on shares of Strongbridge Biopharma in a research report on Monday, March 12th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Strongbridge Biopharma has an average rating of “Buy” and a consensus price target of $12.81.
A number of hedge funds have recently modified their holdings of SBBP. Wells Fargo & Company MN lifted its holdings in Strongbridge Biopharma by 1,130.4% in the 4th quarter. Wells Fargo & Company MN now owns 44,640 shares of the biotechnology company’s stock worth $324,000 after buying an additional 41,012 shares in the last quarter. BlackRock Inc. lifted its holdings in Strongbridge Biopharma by 57.5% in the 4th quarter. BlackRock Inc. now owns 1,432,365 shares of the biotechnology company’s stock worth $10,385,000 after buying an additional 522,875 shares in the last quarter. Opaleye Management Inc. lifted its holdings in Strongbridge Biopharma by 5.9% in the 4th quarter. Opaleye Management Inc. now owns 1,250,000 shares of the biotechnology company’s stock worth $9,062,000 after buying an additional 70,000 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Strongbridge Biopharma in the 4th quarter worth $1,813,000. Finally, Geode Capital Management LLC lifted its holdings in Strongbridge Biopharma by 20.7% in the 4th quarter. Geode Capital Management LLC now owns 79,093 shares of the biotechnology company’s stock worth $573,000 after buying an additional 13,554 shares in the last quarter. Hedge funds and other institutional investors own 58.21% of the company’s stock.
Strongbridge Biopharma traded up $0.15, reaching $7.80, during trading on Thursday, MarketBeat Ratings reports. 498,871 shares of the company’s stock were exchanged, compared to its average volume of 248,016. The company has a current ratio of 4.88, a quick ratio of 4.84 and a debt-to-equity ratio of -3.17. Strongbridge Biopharma has a 52-week low of $7.75 and a 52-week high of $8.60. The stock has a market cap of $357.42 million, a price-to-earnings ratio of -5.38 and a beta of 1.04.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com